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ABSTRACT: The aim of this study was to investigate whether asthma is asso-
ciated with decreased quality of sleep and increased daytime sleepiness.
The study involved a random population of 2,202 subjects supplemented by
459 subjects with suspected asthma, aged 20–45 yrs. The subjects were from
Reykjavik (Iceland), Uppsala and Göteborg (Sweden) and Antwerp (Belgium),
and participated in the European Community Respiratory Health Survey. The
investigation included a structured interview, methacholine challenge, skin-
prick tests and a questionnaire on sleep disturbances. Participants in Iceland
and Sweden also estimated their sleep times and made peak expiratory flow
(PEF) recordings during a period of 1 week. Asthma was defined as self-report-
ed physician-diagnosed asthma with current asthma-related symptoms (n=267).
Difficulties inducing sleep (DIS) and early morning awakenings (EMA) were
about twice as common, and daytime sleepiness 50% more common, in asth-
matics compared with subjects without asthma. After adjusting for possible
confounders, a positive association was found between asthma and: DIS (odds
ratio (OR)=1.8); EMA (OR=2.0); daytime sleepiness (OR=1.6); snoring (OR=1.7);
and self reported apnoeas (OR=3.7). Allergic rhinitis, which was reported by
71% of subjects with asthma, was independently related to DIS (OR=2.0) and
daytime sleepiness (OR=1.3). A significant correlation was found between the
number of asthma-related symptoms and sleep disturbances (p<0.001).
Asthma is associated with decreased subjective quality of sleep and increased
daytime sleepiness. Concurrent allergic rhinitis may be an important under-
lying cause of sleep impairment in asthmatic patients.
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Recent studies indicate that the prevalence of asthma
in adults in northern Europe may now be as high as
5–8% [1–3]. Many patients with asthma experience
symptoms at night [4, 5] and several studies have shown
that the quality of sleep in such patients is decreased
[6–8]. Studies from general population samples have
also found that subjects with asthma have a decreased
quality of sleep when compared with subjects without
asthma [9–12]. The results of these studies are, how-
ever, somewhat contradictory, as increased daytime
sleepiness in asthmatics has been found in some inves-
tigations [9–11], but not in the most recent population
study [12]. A possible disadvantage in previous popu-
lation studies on asthma and sleep disturbances is that
they have been based only on questionnaire findings
and have not included objective measurements.
Between 1990 and 1993, an epidemiological investi-
gation into the prevalence of asthma and allergy, The
European Community Respiratory Health Survey (ECRHS),
was conducted in different centres throughout the world
[13]. In the first part of this study, a large population
of randomly selected adults, in the age range 20–44 yrs,
answered a postal questionnaire. The second and more
extensive part comprised a random sample of the first
population supplemented by subjects for whom the postal
questionnaire indicated suspected asthma. In four of the
participating centres: Reykjavik in Iceland, Uppsala and
Göteborg in Sweden, and Antwerp in Belgium, a ques-
tionnaire relating to sleep disturbances was added to the
second part of the ECRHS study. One purpose of this
questionnaire was to compare the prevalence of sleep
complaints in randomly selected populations from dif-
ferent countries using the same methodology [14, 15].
The aim of the present investigation was to study the
possible association between asthma and quality of sleep.
A secondary aim was to assess possible underlying mech-
anisms that may cause an impaired quality of sleep in
subjects with asthma.
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Population and methods 
Study areas and target populations
The subjects in this study came from four centres: 1)
Reykjavik, the capital of Iceland, and surrounding sub-
urbs, with an approximate population of 160,000; 2)
Uppsala, the fourth largest city in Sweden, with approx-
imately 170,000 inhabitants; 3) Göteborg, the second
largest city in Sweden. The study area comprised the
northern part of the city on the island of Hisingen, with
an  approximate population of 110,000; and 4) Antwerp,
the second largest city in Belgium. The study area com-
prised the centre of the city and 13 municipalities in
the southern suburban area, with a target population of
300,000 inhabitants from a total of approximately 750,000.
Populations
In phase one of the ECRHS, a random sample, in the
age range 20–44 yrs, was selected using the population
register at each centre (fig. 1). A postal questionnaire
was sent to all subjects. The number of subjects select-
ed was 3,600 in Reykjavik, Uppsala and Göteborg and
8,029 in Antwerp, and the response rate to the ques-
tionnaire was 81, 87, 80 and 75%, respectively. A ran-
dom sample of those answering the questionnaire in
Reykjavik (n=800), Uppsala (n=705) Göteborg (n=772)
and Antwerp (n=1,665) was invited to participate in
the second phase of the study. This phase included a
structured interview, measurement of lung function and
allergy testing. The number of subjects who participat-
ed in the second phase of the study was 570 (71%), 623
(88%), 682 (88%) and 1,121 (67%) in Reykjavik, Uppsala,
Göteborg and Antwerp, respectively. A further sample
of all the subjects who, in the postal questionnaire,
reported nocturnal attacks of breathlessness, attacks of
asthma or current use of medication for asthma was also
selected for this further study: Reykjavik n=90, Uppsala
n=216, Göteborg n=226 and Antwerp n=230 (fig. 1). The
informed consent of all participants was obtained and
the study was approved by all the Ethics Committees
involved.
The screening questionnaire and the questionnaire
used in the structured interview were based on the Inter-
national Union Against Tuberculosis and Lung Disease
(IUATLD) questionnaire [13, 16]. In the interview, the
patients answered questions relating to respiratory symp-
toms, respiratory disorders, medication and environ-
mental factors. Asthma was defined as reporting: 1) ever
having had asthma where the diagnosis had been con-
firmed by a doctor; and 2) having at least one asthma-
related symptom in the last 12 months. 
Asthma related symptoms were defined as reporting:
1) wheezing or whistling in the chest; 2) wheezing in
combination with breathlessness, and wheezing when
not having a cold; or 3) having had an attack of short-
ness of breath that came during the day when at rest,
or following strenuous activity. The number of asthma-
related symptoms reported was used for calculating an
asthma symptom score.
Allergic rhinitis was defined as reporting having nasal
allergy including hay fever.
Lung function and bronchial hyperresponsiveness 
Forced expiratory volume in one second (FEV1) was
measured in 2,167 persons using the Spiro Medics com-
puterized dry-rolling seal spirometer system 2130 (Sensor
Medics, Anaheim, CA, USA). The predicted values were
calculated for each patient [17].
Methacholine challenge was performed in 1,980 indi-
viduals using a Mefar dosimeter (Mefar, Brescia, Italy)
[18]. Patients with a decrease in FEV1 of 20% with an
accumulated methacholine dose of ≤2 mg were defined
as having bronchial hyperresponsiveness (BHR) [19, 20].
All the participants in Uppsala and Göteborg and a
random sample of 25% of the participants in Reykjavik,
Fig. 1.  –  Population selection and participation rates.  In total, 2,202 of the random sample, and 459 of the symptomatic sample, answered the
sleep questionnaire. 
Screening
questionnaire
Answered
questionnaire
3,600 3,600 3,600 8029
2,903 (81%) 3,147 (87%) 2,884 (80%) 6,027 (75%)
¨
Answered sleep
questionnaire
535  +  78
 (94  +  93%)
 542  +  182
  (87  +  91%)
426  +  114
 (62  +  62%)
699  +  85
 (62  +  53%)
Random + symptomatic
sample
800  +  90 705  +  216 772  +  226 1,665  +  230
Participated
in study
570  +  84
 (71  +  93%)
623  +  201
 (88  +  93%)
682  +  184
 (88  +  81%)
1,121  +  162
    (67  +  70%)
Reykjavik
 Iceland
Uppsala
Sweden
Goteborg
 Sweden
Antwerp
Belgium
and all of those with symptoms indicating asthma were
asked to record peak expiratory flow (PEF) (the best of
three measurements) twice daily for 1 week with a mini-
Wright peak flow meter (Clement Clarke, London, UK).
The number of patients who managed to record PEF
measurements twice a day on at least 4 of 7 days was
155 in Reykjavik, 552 in Uppsala and 533 in Göteborg.
PEF variability was calculated by dividing the differ-
ence between the highest and lowest daily PEF reading
by the daily mean PEF value [21].
Allergy testing
Skin-prick test with the Phazet (Pharmacia Diagnostics,
Uppsala, Sweden) was conducted on 2,144 individuals.
Individuals with a positive prick test (weal with a mean
diameter of ≥3 mm) to at least one of the following aller-
gens: birch, timothy, mugwort, Dermatophagoides ptero-
nyssinus, cat, dog, Cladosporium herbatum or Alternaria
alternata were defined as having atopy [19, 20]. Individuals
with a positive skin-prick test to D. pteronyssinus were
defined as being house dust mite sensitive.
Sleep questionnaire 
After completing the interview and examination, all
the subjects were asked to fill in a separate question-
naire addressing their quality of sleep during the last
few months. The questionnaire was a slightly modified
version of a questionnaire used in previous Swedish and
Icelandic studies [10, 11, 22]. The questionnaire, which
has been described in detail in a previous paper [15],
comprised 16 questions: 14 multiple choice questions,
giving answers expressed as discontinuous variables on
a nominal scale, and two other questions giving an-
swers expressed as continuous variables on a interval
scale. For the multiple choice questions, the subjects
were asked to estimate the frequency of different symp-
toms on a five-point scale: 1=never; 2=less than once
a week; 3=1–2 nights a week; 4=3–5 nights a week;
5=almost nightly/daily. For the other two questions, the
subjects were asked to estimate the average time it took
them to fall asleep in the evening and the average num-
ber of nocturnal awakenings. The questionnaire was
translated and then back translated from Swedish to
Dutch to enable it to be used in Antwerp. The number
of subjects who completed the sleep questionnaire was
613, 724, 540 and 784 in Reykjavik, Uppsala, Göteborg
and Antwerp, respectively (fig. 1).
Sleep diary 
In Reykjavik, Uppsala and Göteborg, sleep habits were
also investigated by means of a sleep diary of a type
that has been used previously in studies in Iceland and
Sweden [11, 22]. The participants were instructed to
make entries in the diary shortly after waking each morn-
ing. They used a broken line to indicate the time in bed
before they fell asleep, and an unbroken line for the
time they slept. Awakenings were shown by gaps in the
unbroken line. The sleep diaries were analysed, using
computerized digital analysis in Reykjavik [11, 22]. For
each week, estimated total sleep time, time awake at
night and sleep efficiency (sleep time divided by time
spent in bed at night) was calculated from the diary. All
the participants in Uppsala and Göteborg and a random
sample of 25% of the participants in Reykjavik, and all
of those with symptoms indicating asthma were asked
to fill in the sleep diary. The number of subjects that
completed the diary correctly was 166 in Reykjavik, 536
in Uppsala and 486 in Göteborg.
Statistics
The statistical analysis was performed with the Statistica
4.0 software package (StatSoft Inc, Tulsa, USA). The
variation in the prevalence of sleep disturbances and
sleep times in subjects with and without asthma was
studied using the Chi-squared test and unpaired t-test.
Correlations between single variables (sleep disturbances,
symptom score, FEV1 and PEF variability) were stud-
ied with Spearman's rank correlation. The influence of
combined variables on reported sleep and daytime dis-
turbances (expressed as discontinuous variables on a
nominal scale) was analysed using logistic regression
analysis. The influence of combined variables on esti-
mated sleep, time awake at night and sleep efficiency
(expressed as continuous variables on an interval scale)
was estimated using multiple linear regression. In order
to obtain an approximate normal variation in the depen-
dent variables, a log transformation (log (x+1)) was per-
formed on sleep latency and time awake at night. A
p-value of less than 0.05 was regarded as statistically
significant.
Results 
Asthma and sleep disturbances 
The demographic characteristics of the group of sub-
jects with and without asthma is presented in table 1.
Subjects with asthma had a significantly higher preva-
lence of difficulties inducing sleep (DIS), early morn-
ing awakenings (EMA), snoring, self-reported apnoeas,
daytime tiredness (feeling physically tired during day-
time), daytime sleepiness (feeling drowsy in the day-
time), higher number of nocturnal awakenings, longer
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Table 1.  –  Characteristics of subjects with and without
asthma
No asthma Asthma
(n=2,394) (n=267)
Age  yrs 33±7 33±7
Females  % 54 55
Smoker  % 36 36
BHR  % 13 71***
Atopy  % 31 67***
Mite sensitization  % 11 22***
Allergic rhinitis  % 28 71***
Oral theophylline  % 0.2 9.8***
FEV1 % pred  107±12 100±14***
PEF variability  % 4±3 7±6***
Values are presented as percentage or as mean±SD.  BHR:
bronchial hyperresponsiveness;  FEV1:  forced expiratory vol-
ume in one second;  % pred:  percentage of predicted value;
PEF:  peak expiratory flow.  ***:  p<0.001, compared to sub-
jects without asthma.
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time awake at night and lower sleep efficiency than sub-
jects without asthma (table 2). These associations were
also found when populations from each centre were stud-
ied separately but the differences were not always statis-
tically significant. The only exception to this was that
in Uppsala no trend towards a higher prevalence of snor-
ing was found in subjects with asthma compared to sub-
jects without asthma.
Multiple logistic regression with adjustment for pos-
sible confounders showed independent associations bet-
ween asthma and DIS, EMA, daytime tiredness, daytime
sleepiness, snoring and apnoeas (table 3 and 4). When
multiple linear regression was performed, asthma cor-
related weakly but significantly with sleep latency (r=0.05)
and sleep efficiency (r=0.06) (p<0.05).
In order to study whether the use of an enriched pop-
ulation sample may have biased the results, the multi-
ple logistic regression analysis was repeated in the random
sample. The odds ratios (95% confidence interval) for
the association between physician diagnosed asthma
and night or daytime disturbances were: DIS 1.9 (0.96–
3.7); EMA 2.6 (1.3–5.0); daytime sleepiness 1.7 (1.04–2.9);
daytime tiredness 1.4 (0.8–2.4); snoring 1.8 (0.9–3.3)
and self reported apnoeas 5.8 (1.9–18).
Asthma-related variables and sleep disturbances 
As expected, the group of subjects with asthma had
a higher prevalence of BHR, atopy, sensitization to house
dust mite and allergic rhinitis, as well as lower FEV1
and higher PEF variability than subjects without asthma
(table 1). Using univariate analysis, BHR was related
to increased prevalence of daytime tiredness (20.2 vs
12.4%, for those with BHR and without, respectively;
p<0.001), daytime sleepiness (21.7 vs 15.9%; p<0.01),
EMA (8.8 vs 5.6%; p<0.05), longer time awake at night
(15±22 vs 12±22 min) (mean±SD) (p<0.01) and decreased
sleep efficiency (95±6 vs 96±6%; p<0.05). Allergic rhini-
tis was associated with increased prevalence of DIS
(10.2 vs 6.1%), daytime tiredness (18.7 vs 13.3%), day-
time sleepiness (21.1 vs 15.2%) (p<0.001), longer time
awake at night (16±27 vs 12±19 min) and decreased
sleep efficiency (95±7 vs 96±6%) (p<0.01). The use of
theophylline was related to an increased prevalence of
DIS (22.6 vs 7.2%) (p<0.001) and decreased sleep effi-
ciency (91±7 vs 95±6%; p<0.01). FEV1 was negatively
correlated with the daytime tiredness score (r=0.05,
p<0.05), while PEF variability was positively correlat-
ed to time awake at night (r=0.10) (p<0.001), and sleep
efficiency (r=0.07) (p<0.05). No significant association
was found between atopy or mite sensitization and the
quality of sleep.
Multiple logistic regression with adjustment for pos-
sible confounders showed an independent association
between rhinitis and DIS, daytime tiredness and day-
time sleepiness, while BHR was independently related
to daytime tiredness (table 5). No significant associa-
tion was found between snoring or apnoeas and any of
the asthma-related variables. When multiple linear regres-
sion was performed, rhinitis correlated independently
with time awake at night (r=0.07; p<0.05) and sleep
efficiency (r=0.09; p<0.01). PEF variability correlated
independently with time awake at night (r=0.07; p<0.05).
Table 2.  –  The prevalence of sleep disturbance and
sleep times in patients with and without asthma
No asthma Asthma
(n=2,394) (n=267)
Difficulties inducing sleep 6.8 12.7***
(≥3 per week)
Early morning awakenings 5.7 11.2***
(≥3 per week)
Nightmares (≥1 per week) 5.0 5.7
Snoring (≥3 per week) 9.2 14.7**
Apnoea (≥1 per week) 1.2 3.8***
Daytime tiredness (≥3 per week) 14.1 23.2***
Daytime sleepiness (≥3 per week) 16.0 26.8***
Sleep latency  min 19±23 22±26**
Nocturnal awakenings  n·night-1 1.1±1.2 1.6±1.6***
Total sleep time  min 450±80 453±100
Time awake at night  min 13±22 15±22***
Sleep efficiency  % 96±6 94±6**
Values are presented as percentage or as mean±SD.  **:  p<0.01;
***:  p<0.001, compared to subjects without asthma.
Table 3.  –  Multiple regression analysis of risk factors for sleep disturbance and daytime symptoms
Difficulties Early morning Daytime Daytime
inducing sleep awakenings sleepiness tiredness
Asthma 1.8 (1.2–2.7)** 1.9 (1.2–2.9)** 1.5 (1.1–2.1)** 1.4 (1.03–2.0)*
Female 1.0 (0.7–1.4) 1.0 (0.7–1.4) 1.7 (1.4–2.1)*** 1.8 (1.4–2.3)***
Age† 1.2 (0.9–1.5) 2.0 (1.6–2.6)*** 0.7 (0.6–0.8)*** 0.9 (0.8–1.1)
Smoking 1.9 (1.4–2.6)*** 1.0 (0.7–1.4) 1.0 (0.8–1.3) 1.4 (1.1–1.8)**
Snoring 1.3 (0.8–2.1) 1.4 (0.8–2.2) 2.0 (1.5–2.8)*** 1.9 (1.4–2.7)***
Gastro-oesophageal reflux 3.5 (2.2–5.4)*** 4.1 (2.6–6.5)*** 2.6 (1.8–3.8)*** 4.2 (2.9–6.0)***
BMI ≥25 kg·m-2 1.1 (0.7–1.6) 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.1 (0.9–1.3)
†:  OR for increased risk of sleep disturbance for each 10 yr increase in age.  The values presented are odds ratio, and 95% con-
fidence interval in parenthesis, after adjustment for area of residence and all independent variables in the table.  OR:  odds ratio;
BMI:  body mass index.  *:  p<0.05;  **:  p<0.01;  ***:  p<0.001, for the relationship between the dependent and independent
variables.
Table 4.  –  Multiple regression analysis of risk factors
for self-reported snoring and apnoeas
Snoring Apnoeas
Asthma 1.7 (1.2–2.5)** 3.7 (1.7–7.9)***
Male 2.4 (1.8–3.3)*** 3.2 (1.5–6.7)**
Age† 1.7 (1.4–2.2)*** 1.9 (1.2–3.2)**
Smoking 1.2 (0.9–1.6) 1.9 (0.98–3.6)
BMI ≥25 kg·m-2 2.2 (1.6–2.9)*** 1.2 (0.6–2.4)
†:  OR for increased risk of sleep disturbance for each 10 yr
increase in age. The values presented are odds ratio, and 95%
confidence interval in parenthesis, after adjustment for area
of residence and all independent variables in the table.  OR:
odds ratio;  BMI:  body mass index.  **:  p<0.01;  ***:
p<0.001, for the relationship between the dependent and inde-
pendent variables.
Asthma-related symptoms 
A significant correlation was found between the num-
ber of asthma-related symptoms and the score for all
sleep disturbance variables. Asthma symptoms score was
also significantly correlated with sleep latency, time
awake at night and sleep efficiency (table 6).
Nonparticipants
When comparing nonparticipants and participants in
the randomly selected sample, it was found that in
Antwerp the proportion of males who answered the sleep
questionnaire was lower than in the sample who did not
answer the questionnaire (43 vs 50%; p<0.001). Mean
age was slightly higher in subjects who answered the
sleep questionnaire in Reykjavik (33 vs 32 yrs; p<0.05)
and Göteborg (34 vs 32 yrs; p<0.001) than among sub-
jects who did not answer the questionnaire. In Uppsala
the proportion of females (56 vs 45%) was higher in the
group who filled in the diary compared to the group who
only completed the questionnaire. Mean age was slight-
ly higher among participants in Göteborg and Reykjavik
who filled in the sleep diary (34 vs 32 and 35 vs 33 yrs;
p<0.01) compared to subjects who only answered the
sleep questionnaire. In Göteborg there was a lower preva-
lence of nightmares (≥1 per week) (6 vs 13%) and early
morning awakenings (4 vs 10%) (p<0.05) in subjects
who filled in the diary than in those who did not.
Otherwise there were no significant differences between
subjects who answered both the diary and the ques-
tionnaire and those who only answered the question-
naire.
Discussion
In this study, we found that asthma is associated with
a decreased quality of sleep. The prevalence of diffi-
culties inducing sleep and early morning awakenings
was about twice as high and the prevalence of daytime
sleepiness 50% higher in asthmatic subjects compared
to those without asthma. Asthmatic subjects as a group
also had slightly lower sleep efficiency and a higher
number of nocturnal awakenings than the rest of the
population. In order to investigate the possible under-
lying mechanism causing impaired quality of sleep
in asthmatic subjects, the association between asthma-
related variables and sleep disturbances was analysed.
In the multivariate analysis, allergic rhinitis was found
to be independently associated with DIS, daytime tired-
ness and daytime sleepiness, while BHR was associat-
ed only with daytime tiredness. Rhinitis and PEF variability
were both weakly related to the time spent awake at
night.
An increased prevalence of sleep disturbances in asth-
matic subjects has been reported in other studies [9–12].
KLINK and QUAN [8], in a study from the Tucson Epidem-
iological Study of Chronic Lung Diseases, found that
subjects with obstructive lung disease had more prob-
lems inducing and maintaining sleep and more daytime
sleepiness than subjects without obstructive lung dis-
ease. However, when separating subjects with asthma
from those with chronic bronchitis, no significant asso-
ciation was found between asthma alone and difficulties
inducing and maintaining sleep or daytime sleepiness.
GISLASON and ALMQVIST [10] reported higher prevalence
of difficulties maintaining sleep and daytime sleepiness
in subjects with asthma or chronic bronchitis in a study
of middle-aged men. In a previous study from one of
our departments [11], hospital out-patients with asthma
were compared with matched subjects without asthma
from a population study. A higher prevalence of DIS,
difficulties maintaining sleep and daytime sleepiness
was found in patients with asthma in this study [11]. In the
most recent general population-based study, FITZPATRICK
et al. [12] found that asthmatic subjects reported less
refreshing sleep than nonasthmatics. However, the authors
found no difference in the prevalence of daytime sleepi-
ness between asthmatics and nonasthmatics.
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Table 5.  –  Multiple regression analysis of asthma-related risk factors for sleep disturbance and daytime symptoms
Difficulties Early morning Daytime Daytime
inducing sleep awakenings sleepiness tiredness
BHR 0.9 (0.5–1.4) 1.3 (0.8–2.1) 1.3 (0.95–1.8) 1.4 (1.1–2.2)*
Rhinitis 2.0 (1.4–2.9)*** 1.4 (0.9–2.0) 1.3 (1.04–1.8)* 1.4 (1.05–1.9)*
Theophylline 2.5 (0.7–9.6) 2.5 (0.6–10.0) 1.9 (0.6–6.0) 0.2 (0.02–1.7)
FEV1 % pred† 1.1 (0.9–1.2) 1.1 (0.9–1.2) 1.1 (0.97–1.2) 1.0 (0.9–1.1)
†:  OR for increased risk of sleep disturbance for each 10 yr increase in age.  The values presented are odds ratio, and 95% con-
fidence interval in parenthesis, after adjustment for area of residence, gender, age, body mass index, reported snoring and gastro-
oesophageal reflux. For definitions see legend to table 1.  *:  p<0.05;  ***:  p<0.001, for the relationship between the dependent
and independent variables.
Table 6.  –  Associations between number of asthma-
related symptoms during the last 12 months and sleep
disturbance and sleep times
Symptoms
None 1 2 3
(n=1578) (n=562) (n=293) (n=228)
DIS (≥3 per week) 4.7 9.5 12.3 14.0
EMA (≥3 per week) 4.4 6.6 10.2 13.3
Snoring (≥3 per week) 8.0 8.4 16.3 16.7
Apnoeas (≥1 per week) 1.2 1.3 2.4 2.7
Day time tiredness 10.9 18.5 21.8 25.8
(≥3 per week)
Day time sleepiness 13.1 21.8 23.2 24.6
(≥3 per week)
Sleep latency  min 16±18 22±28 25±30 24±32
Time awake at night  min 11±19 15±28 19±26 14±18
Sleep efficiency  % 96±6 95±7 94±7 94±6
Values are presented as percentage, or as mean±SD.  DIS:  dif-
ficulties inducing sleep;  EMA:  early morning awakenings.
Asthma-related symptom score was significantly correlated
with all listed variables (p<0.001).
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Apart from the association of asthma with DIS, noc-
turnal and early morning awakenings, daytime sleepiness
and daytime tiredness, we also found a higher preva-
lence of snoring and self-reported apnoeas among asth-
matics than nonasthmatics. An increased prevalence of
snoring among asthmatics has previously been report-
ed by FITZPATRICK et al. [12]. Other studies have indi-
cated possible associations between the obstructive sleep
apnoea syndrome and nocturnal asthma [23, 24]. LIN
and LIN [25] found an increased prevalence of BHR in
16 patients with obstructive sleep apnoea compared to
a control group. They also reported a reduction in BHR
after 2–3 months of continuous positive airway pressure
(CPAP) treatment. In our study, however, we were unable
to find an association between BHR and snoring or
apnoeas.
We do not know of any previous epidemiological
study that has investigated the relationship between aller-
gic rhinitis and the quality of sleep. However, JUNIPER
and GUYATT [26] found that many patients with allergic
rhinitis experience sleep impairment during an allergy
season, when they were developing a quality of life
questionnaire for clinical trials. JUNIPER and co-workers
[27] also showed that this sleep impairment could be
reduced with regular treatment with topical corticos-
teroids. Increased nasal resistance may also be a con-
tributing factor in the pathogenesis of obstructive sleep
apnoea [28]. In our study, however, we found no sig-
nificant association between allergic rhinitis and snor-
ing or self-reported apnoeas.
Theophylline, which is chemically related to caffeine,
has also been implicated as a possible factor in decreas-
ing quality of sleep in asthma [29]. In the multivariate
analysis, no significant association was found between
the use of theophylline and the quality of sleep. As only
10% of the subjects with asthma used theophylline, the
power to detect a significant relationship between the
use of theophylline and impaired quality of sleep was,
however, low in this study. No association was found
between sensitization to house dust mite and the qual-
ity of sleep.
We have previously reported that in asthmatics sub-
jective quality of sleep is related to disease activity [11].
In this study, we found a negative correlation between
the number of asthma-related symptoms and quality of
sleep. This result is in accordance with a recent study
from Tucson, in which a significant relationship was found
between the rates of respiratory symptoms and sleep
complaints [30].
The definition of asthma used in this study was based
on self-reported physician diagnosed asthma. This defin-
ition has been suggested by some investigators as opti-
mal for epidemiological studies as it has a high specificity
for clinical asthma [31]. In order to exclude subjects
who had asthma only in childhood, only those indivi-
duals who reported having had asthma-related symp-
toms in the last 12 months were included. As adults
over the age of 45 yrs were not included, most of the
problems of separating asthma from chronic obstructive
pulmonary disease, were probably avoided.
In order to increase the number of asthmatic subjects
in the study, an enriched population sample was used.
Repeating the multiple logistic regression analysis in
the randomly selected population, however, did not
significantly alter the odds ratios for the association be-
tween asthma and sleep disturbances or daytime sleepi-
ness. Therefore, we do not believe that the use of an
enriched sample biased the results in this study. In the
multivariate analysis, adjustments were made for those
variables that we have previously found to be signifi-
cantly related to sleep disturbances in a general popu-
lation. Variables, such as seasonal variation or caffeine
consumption, that were not previously found to be sig-
nificantly related to the quality of sleep were, however,
not included in the analysis [14, 15]. As in our previous
reports, we found a strong association between reported
nocturnal gastrooesophageal reflux (heartburn or belch-
ing after going to bed) and sleep disturbances.
The questionnaire used in this study is based on the
Basic Nordic Sleep Questionnaire (BNSQ) [32]. The
main change in the BNSQ compared to many earlier
sleep questionnaires is the introduction of a five-point
scale indicating how many nights/days per week symp-
toms occur. This facilitates comparisons when the ques-
tionnaire is used in different countries. This scale for
quantifying subjective sleep complaints is now widely-
used in the Nordic countries, as well as in some stud-
ies from other countries [32, 33]. In this study, the use
of three different languages carries the possibility of a
translation bias. As we have reported from our previous
analysis of the randomly selected sample, the variation
in the prevalence of sleep disturbances between the two
Swedish centres was, however, of the same magnitude
as that between the Swedish and non-Swedish centres
[14, 15]. Therefore, we do not think that translation bias
was a major problem in this study.
We conclude that asthma is associated with decreased
subjective quality of sleep and increased daytime sleepi-
ness. Concurrent allergic rhinitis may be an important
underlying cause for sleep impairment in asthmatic
patients. This study confirms the need to include ques-
tions about sleep characteristics in asthma questionnaires
for clinical studies or quality of life assessment.
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